The Frequency of Withdrawal from Acute Care Is Impacted by Severe Acute Renal Failure by Swartz, Richard D. et al.
JOURNAL OF PALLIATIVE MEDICINE
Volume 7, Number 5, 2004
© Mary Ann Liebert, Inc.
The Frequency of Withdrawal from Acute Care Is
Impacted by Severe Acute Renal Failure
RICHARD SWARTZ, M.D., ERICA PERRY, M.S.W., and JAMIE DALEY
ABSTRACT
Introduction: In the general intensive care setting, decisions to withdraw life support when
patients deteriorate despite aggressive treatment are estimated to occur in 10% of all patients
and in 40% of the patients who die. Acute renal failure (ARF) severe enough to necessitate
renal replacement therapy (RRT) is associated with in-hospital mortality approximating 50%.
Yet the impact of severe ARF on decisions to withdraw treatment has not been previously de-
scribed. In chronic renal failure patients, voluntary withdrawal from maintenance dialysis oc-
curs in 10%–20% of patients when increasing complications and poor quality of life ensue,
and knowing these data facilitates discussions with patients and families. Having similar data
for complicated ARF would facilitate decision making for families and caregivers when these
difficult situations arise.
Methods: All cases of ARF requiring RRT during 2000–2001 at University of Michigan Hos-
pital (n  383) were entered prospectively into an outcome study at the time RRT was initi-
ated. Comprehensive data collection included demographic and clinical characteristics, out-
come and complications, and severity of illness. Additional information for patients who died
included cause of death, life-support withdrawal decisions, and the presence of prior advance
directives.
Results: Overall mortality in severe ARF (i.e., severe enough to require RRT) was 53%. Life-
support withdrawal occurred in 72% of deaths (compared to 40%–50% reported among gen-
eral intensive care cases) and was associated with intensive care stay well beyond 2 weeks.
Severity of illness, as indicated by modified APACHE III scores, was higher in patients who
died than in survivors, but severity of illness was not higher for withdrawal from treatment
than death without withdrawal decisions. Life-support withdrawal was not associated with
other demographic or clinical characteristics (hospital service, primary admitting diagnosis,
ventilator or pressor dependence, sepsis, or initial type of RRT chosen). Prior advance direc-
tives were available in 29% of patients overall, but having advance directives did not predict
withdrawal from acute treatment. Death occurred within 2 days of withdrawal in more than
90% of cases, emphasizing the severity of underlying illness.
Conclusions: Severe ARF reflects the severity of underlying illness, impacts overall survival,
and is associated with more frequent withdrawal from aggressive treatment. High severity of
illness and prolonged intensive care without improvement beyond 2 weeks presage decisions
to withdraw treatment and signal patients and caregivers that death is imminent and that fur-
ther aggressive care should be reconsidered or limited.




THE MORTALITY OF ACUTE RENAL FAILURE (ARF)severe enough to require renal replacement
therapy (RRT) is approximately 50%1–3 and is re-
lated largely to underlying comorbidity.4–6 RRT
can save some lives, and newer RRT modalities
such as continuous RRT may have some advan-
tages.6–9 But ARF patients with multisystem ill-
ness often have difficult courses and succumb de-
spite aggressive medical care and state-of-the-art
RRT. There are now a number of scoring systems
for predicting mortality generally in complex
medical cases10,11 and more specifically in the set-
ting of severe ARF.1,5,12 Yet these scoring systems
can only predict outcome on the basis of specific
objective clinical data and cannot account for the
“human” factor in the decision-making by fami-
lies and caregivers.13,14
The setting of renal failure and RRT treatment
is one in which end-of-life discussions have be-
come a more frequent phenomenon. In long-term
maintenance dialysis (end stage renal disease
[ESRD]), patients and families often realize the
limitations of long-term treatment and are told
that a generally quiet death usually occurs within
2 weeks of withdrawal.15,16 As a result, a volun-
tary decision to withdraw from dialysis occurs in
10%–20% of ESRD deaths.15,17,18 However, the
degree to which patients with ARF make these
types of decisions is not well established. Deci-
sions to limit or withdraw care have been esti-
mated to occur in approximately 10% of all cases
and in 40%–50% of all deaths in intensive care
units both in the United States and in the United
Kingdom,19–21 but such data are sparse and not
generally recognized. Given the substantial con-
tribution of ARF to hospital mortality, we hy-
pothesize that ARF necessitating RRT increases
not only the complexity of illness but also the like-
lihood of withdrawal from treatment.
METHODS
All patients with severe ARF (i.e., severe
enough to require RRT) at University of Michi-
gan Hospital are entered prospectively into com-
prehensive data collection at the onset of RRT. Pa-
tients with ARF who receive RRT are identified
from the nursing treatment records of the Acute
Dialysis Unit, so that all such are patients are in-
cluded in this review. Patients with moderate or
severe chronic renal failure approaching end-
stage renal disease (glomerular filtration rate
[GFR] below 25% of normal), any history of prior
long-term dialysis or prior kidney transplant are
excluded from this analysis.
The database includes demographic and co-
morbidity information, primary admitting diag-
nostic category, laboratory results, characteristics
of treatment, complications, specific time inter-
vals during hospital stay (admission to first day
of RRT, duration of RRT, duration of intensive
care unit stay, time from withdrawal decision to
death, and total hospital days) and outcomes
(death in hospital, discharge with renal recovery
of renal function sufficient to obviate the need for
dialysis, or discharge on maintenance dialysis
with end-stage renal disease or ESRD). The gen-
eral character of this database has been previ-
ously described.6
Included with these data are any specific and
clear decisions to withdraw aggressive support-
ive treatment (RRT, ventilator, pressor medica-
tions) that are documented in medical record
progress notes. These decisions were identified
“prospectively” in real-time chart review when-
ever possible, and included the presence of both
specific daily progress notes and a do not resus-
citate order. In addition, the generic availability
(but not necessarily the content) of advance di-
rectives and the general category of illness lead-
ing directly to the withdrawal decision and/or
death itself (e.g., bleeding, cardiac, neurologic, or
infection) were determined retrospectively by
chart review but were not part of the original
comprehensive data collection.
General mortality risk was based on a modi-
fied APACHE III score11 that was calculated for
the day of first RRT treatment rather than on ad-
mission, for patients both in and out of the in-
tensive care units, and with estimation of coma
score from the medical record. Statistical calcula-
tions include Student’s t test and 2 testing where
appropriate.
This study was part of a larger ARF surveil-
lance that was approved by the Institutional Re-
view Board for Human Investigation at Univer-
sity of Michigan Health System.
RESULTS
During the 25-month period between Decem-
ber 1, 1999, and December 31, 2001, 384 patients
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were identified who developed ARF and re-
quired RRT for some period of time. Table 1 lists
the general demographic characteristics and out-
comes among these patients. Overall in-hospital
mortality was 53% (203/384 patients), recovery
of renal function by the time of discharge oc-
curred in 36% (138/384 patients), and mainte-
nance dialysis at discharge was required in 11%
(43/384 patients). Not surprisingly, patients who
died had shorter overall hospital stays and more
severe underlying illness (modified APACHE
III), but older age was not a factor, intensive care
stay was only marginally shorter and total num-
ber of complications was not higher. Not shown
in the table but implied by the data, some deaths
occurred outside of the intensive care unit be-
cause some patients never were in intensive care
or were transferred from intensive care before
death.
Table 2 shows more specific characteristics in
the group of patients who died (n  203). Fully
72% of the patients who died (147/203) had ac-
tive decisions to withdraw from acute care made
by the family (not usually the patient) and care-
givers. Table 2 shows that in comparing these two
subgroups of deceased patients, there was no dif-
ference in the interval between admission and the
start of RRT or the total length of stay. There was
marginally longer intensive care stay among
those patients withdrawn from treatment despite
the slightly shorter total length of stay. With-
drawal from treatment was not associated with
more severe underlying mortality risk or comor-
bidity.
Table 3 shows other specific comorbidity fac-
tors, comparing withdrawal to no withdrawal in
patients who died. Decisions to withdraw from
treatment were not related to the clinical service,
medical versus surgical, even though medical pa-
tients tended to have higher severity of illness,
and withdrawal was not associated with any par-
ticular category of primary admitting illness. The
specific choice of RRT modality also was not re-
lated to withdrawal from treatment, even though
patients triaged to continuous renal replacement
therapy (CRRT) tended to have more severe ill-
ness. Finally, patients withdrawn from treatment
were not more frequently ventilator dependent,
pressor dependent or septic. Not shown in Table
3, neither the immediate category of terminal
complication (cardiac, bleeding, infection, or neu-
rologic) nor the presence of major surgery or or-
gan transplantation characterized patients who
were withdrawn from acute treatment.
Figure 1 shows the time from withdrawal of
treatment to death. In more than 90% of cases,
this time period was short, less than 48 hours.
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TABLE 1. CHARACTERISTICS OF ALL ARF-RRT PATIENTS WITH RESPECT TO OUTCOME
Dieda Recovered ESRD
n 203 (53%) 138 (36%) 43 (11%)
Age (years) 57  16 56  17 64  16b
Gender (female) 41% 40% 47%
Admission to RRT (days) 9  13 7  8 9  12
ICU days 13  13 20  17 15  13
Total hospital days 19  16c 35  27 32  32
Modified APACHE III 97  26c 67  22 69  20
Total complications 5.9  2.0 5.3  2.3c 6.2  2.3
aThe 203 patients who “died” comprise the population for the subsequent data tables.
bSignificantly different (p  0.05) using Student’s t test.
ARF, acute renal failure; RRT, renal replacement therapy; ESRD, end-stage renal disease (chronic dialysis); ICU, 
intensive care unit.
TABLE 2. CHARACTERISTICS OF DECEASED
PATIENTS (n  203) WITH RESPECT TO
WITHDRAWAL FROM ACUTE TREATMENTa
No withdrawal Withdrawal
n 56 147
Age (years) 57  17 57  16
Gender (female) 22 (39%) 60 (41%)
Admission to RRT (days) 10.3  15.8 8.2  11.5
ICU days 13.4  16.6 17.1  10.8
Total hospital days 20.7  20.3 18.1  14.1
Modified APACHE III 96.1  24.4 97.3  27.0
Total complications 6.0  2.0 5.9  2.0
aNo significant differences between groups for any 
values in this table.
RRT, renal replacement therapy; ICU, intensive care
unit.
Shorter time intervals were associated with
higher modified APACHE III scores. Withdrawal
from treatment included pressors and RRT in all
cases, and ventilator in support in most cases in
which such support was in use.
Table 4 shows the availability of prior advance
directives in the medical records of patients who
died. More than 90% of all records were reviewed
for the presence of advance directives (living will
and/or durable power of attorney for medical
decisions). Advance directives were documented
in the medical records for 29% of patients with-
drawn from acute treatment, 35% of patients who
died but were not actively withdrawn from treat-
ment, and 32% of patients of survivors. Thus, the
presence of advance directives did not seem to
predict decisions to withdraw from acute treat-
ment in the population treated at this medical
center.
DISCUSSION
The frequency of withdrawal from life support
treatment in intensive care patients is estimated
to occur in 10% of all patients and is the proxi-
mate cause of death 40%–50% of the time in crit-
ical care units in the United States and the United
Kingdom.19–21 Unpublished data from the med-
ical intensive care unit in our own institution
shows that life-support withdrawal occurred in
11% of all patients and was the proximate cause
of death 41% of the time between 1996 and 2000.
In the present study, withdrawal from acute treat-
ment occurred in 72% of patients who died with
severe ARF, suggesting that severe ARF requir-
ing RRT impacted substantially the decisions that
are made. This review also indicated that death
usually occurred within 48 hours of withdrawing
treatment and was likely the result of a complex
multisystem illness that included severe ARF
rather than the result of “uremia” or the need for
RRT alone.
Even though “futility” is seldom cited directly
in discussions concerning withdrawal of treat-
ment, the rate of withdrawal suggests that the
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TABLE 3. CLINICAL CHARACTER OF DECEASED PATIENTS
RELATIVE TO WITHDRAWAL FROM ACUTE TREATMENT
No withdrawal Withdrawal
n 56 147
Medical patients 34 (61%) 91 (61%)
Mod APACHE III 99.4  21.0a 100.4  29.1a
Surgical patients 22 (39%) 56 (38%)
Mod APACHE III 90.8  24.7a 92.1  21.0a
Primary Diagnosisb
Cardiac (n  36) 13 (23%) 23 (16%)
Heme/onc (n  31) 9 (16%) 22 (15%)
Infect/Pulm/Tr (n  48) 12 (21%) 36 (24%)
Liver (n  61) 15 (22%) 46 (31%)
Vascular (n  27) 7 (13%) 20 (14%)
Initial RRT Modalityc
CRRT (n  130) 37 (66%) 93 (63%)
Mod APACHE III 101.4  26.0a 101.6  27.9a
IHD (n  73) 19 (34%) 54 (37%)
Mod APACHE III 86.2  17.7a 89.7  23.6a
Other comorbidityd
Ventilator (n  138) 38 (68%) 100 (68%)
Pressors (n  127) 33 (59%) 94 (64%)
Sepsis (n  94) 29 (52%) 65 (44%)
aThe modified APACHE III scores for “medical” 
patients were significantly higher than those for surgery
patients, scores for continuous renal replacement therapy
(CRRT) were significantly higher than those for intermit-
tent hemodialysis (IHD), and there were no significant
differences between “withdrawal” and “no withdrawal”
for these groups; all using the Student’s t test.
bPrimary diagnoses prompting hospital admission 
included cardiac, heme/onc (hematology/oncology),
inf/pulm/tr (infection, pulmonary, or trauma), liver or
vascular disease. There were no differences between 
withdrawal and no withdrawal among these diagnoses.
cRenal replacement treatment (RRT) modalities included
continuous RRT (CRRT) or intermittent hemodialysis
(IHD), and there was no difference between withdrawal
and no withdrawal among the RRT modalities. APACHE
scores were higher among CRRT cases, using the Student’s
t test.
dThese characteristics were not mutually exclusive, and
there were no differences between withdrawal and no
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FIG. 1. Distribution of the time from the decision to
withdraw treatment to death in all patients for whom
such decisions were made (n  168). The average modi-
fied APACHE III score (see methods) for each time group
is displayed on the graph, with p  .05 (Student’s t test)
comparing the score for patients dying after 48 hours with
those dying before 48 hours.
discouraging nature of these complicated cases is
evident to all. In some cases, even if families do
not verbalize a definite sense of futility, care-
givers themselves recognize that death is near at
hand. The intuition of caregivers is a reliable pre-
dictor of outcome that often closely approximates
systematic scoring,22–24 but often we do not share
our intuition with patients and families, perhaps
because we cannot explain why some very ill pa-
tients continue to fail and die.14,20 As the course
of intensive care drags on, families soon sense
that death is inevitable, even preferable. That
death comes as swiftly as it does when treatment
is withdrawn signals the complexity of illness in
most of these cases and raises the question of how
long discussion about withdrawal should be de-
ferred.
Several other considerations are raised by the
present study. First, very high overall severity
and the tendency toward a longer portion of the
hospital stay in intensive care that we observed
suggest that the cases we are treating may sim-
ply be more difficult and complex. In fact, we
may be undertaking aggressive intervention and
continuing life support when we might more
wisely defer doing so. Recent data in the general
medical community suggest that utilization of
high cost care with frequent inpatient-consulta-
tive medical services does not necessarily lead to
better outcome.25 The high mortality and with-
drawal rates associated with ARF severe enough
to require RRT prompts us to reconsider how we
triage our technology and, more important, what
we tell patients and families about prognosis and
outcomes.26–28
Second, it is pivotal that we have ongoing and
substantive dialogue with families about how
things are going and whether there is progress or
not.28–30 The construct of a “time-limited trial” of
therapy is very useful when intensive care treat-
ment is prolonged.30 The data presented here
suggest that failure to improve after more than
two weeks in the intensive care unit and prospec-
tive APACHE III score well over 90, signal the
need for discussion of how much longer inten-
sive care should be continued. Our results also
demonstrate to families and caregivers that
demise occurs quickly when support is with-
drawn.
Third, the present study suggests that al-
though prior discussion and advance directives
are important in the setting of chronic illness,
particularly ESRD,29,31,32 the impact of advance
directives may be limited in the acute setting,
particularly in complicated inpatient illness
with severe ARF. Although we did not investi-
gate the nuances of existing advance directives
or the specific content of withdrawal decisions
in the present study, we observed that with-
drawal decisions were made just as often with-
out living will and proxy documents as with
such documents. This conclusion does not den-
igrate the use of such documents but points out
that even now, more than 10 years after the Pa-
tient Self-determination Act of 1990 mandated
consideration of advance directives in federally
funded institutions, this important background
information only has limited impact in the heat
of the moment and may not be specific enough
to dictate exactly what the patient might have
wanted or what we should do. Perhaps it is wise
not to trust our intuition or the available pre-
dictive scores at the beginning of treatment. But
once the course of illness has become more com-
plicated, particularly in cases with ARF and
with clear prospective predictors of high mor-
tality, it may be prudent to pay more attention
to any available advance directives that might
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TABLE 4. PRESENCE OF PRIOR ADVANCE DIRECTIVES FOR DECEASED
PATIENTS RELATIVE TO WITHDRAWAL FROM ACUTE TREATMENTa
Died
No withdrawal Withdrawal Survived
n (record reviewed) 40/56 145/147 168/181
No
Advance Directive 26 (65%) 103 (71%) 114 (68%)
Advance Directive 14 (35%) 42 (29%) 54 (32%)
aA total of 353 of 383 (92%) of records reviewed for advance directives. No significant differences in frequency of
advance directives were demonstrated among the listed groups.
elucidate decisions to withdraw life support
treatment.
CONCLUSION
Fewer than half of the patients who develop
severe ARF requiring RRT will survive to dis-
charge. Among those who die, more than 70% are
withdrawn from aggressive treatments that in-
clude ventilation, pressors and/or RRT, and most
of these patients die within 48 hours of treatment
withdrawal. Although advance directives are
thought to be important in planning medical care,
especially in the chronic care setting, advance di-
rectives did not appear to be a prominent factor
in decisions to withdraw among patients de-
scribed in this study. The present review empha-
sizes that in multiply complex patients with se-
vere renal failure, we must heed our intuitions
when these critically ill patients are failing, share
what we see and know with families and with
patients themselves when possible, and consider
applying limits or proposing time-limited trials
when treatment extends beyond a reasonable
time.
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